Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher.All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...

News Generating Positive Buzz Tempus is a technology company ... The company recently acquired genetic testing pioneer Ambry Genetics in a strategic move to utilize its diagnostics and data ...

Tempus AI reports fourth-quarter revenue of $200.68 million, missing estimates of $203.12 million. Tempus reports a fourth-quarter adjusted loss of 18 cents per share, beating analyst estimates ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...